Jacques Ermolieff

2.2k total citations · 1 hit paper
26 papers, 1.8k citations indexed

About

Jacques Ermolieff is a scholar working on Molecular Biology, Cancer Research and Organic Chemistry. According to data from OpenAlex, Jacques Ermolieff has authored 26 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Organic Chemistry. Recurrent topics in Jacques Ermolieff's work include Computational Drug Discovery Methods (4 papers), Synthesis and biological activity (3 papers) and ATP Synthase and ATPases Research (3 papers). Jacques Ermolieff is often cited by papers focused on Computational Drug Discovery Methods (4 papers), Synthesis and biological activity (3 papers) and ATP Synthase and ATPases Research (3 papers). Jacques Ermolieff collaborates with scholars based in United States, France and Japan. Jacques Ermolieff's co-authors include Theodore Johnson, Michael R. Jirousek, Jordan Tang, Gerald Koelsch, Jeffrey A. Loy, Xinli Lin, Arun K. Ghosh, Dong-Woo Shin, Deborah A. Judd and Craig L. Hill and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Reviews Drug Discovery.

In The Last Decade

Jacques Ermolieff

25 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protein tyrosine phosphatase 1B inhibitors for diabetes

2002 564 citations Theodore Johnson, Jacques Ermolieff et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacques Ermolieff United States	15	932	349	339	299	277	26	1.8k
Daniela Barlocco Italy	28	1.4k 1.4×	137 0.4×	115 0.3×	158 0.5×	986 3.6×	145	2.6k
Qi Sun China	18	612 0.7×	167 0.5×	140 0.4×	210 0.7×	362 1.3×	55	1.4k
J. Uppenberg Sweden	17	2.0k 2.1×	108 0.3×	139 0.4×	93 0.3×	286 1.0×	19	2.3k
Rosaria Ottanà Italy	31	1.0k 1.1×	114 0.3×	84 0.2×	89 0.3×	1.7k 6.3×	78	2.9k
H. van der Goot Netherlands	18	1.0k 1.1×	175 0.5×	77 0.2×	163 0.5×	774 2.8×	60	2.2k
Jung-Ja P. Kim United States	10	758 0.8×	294 0.8×	110 0.3×	105 0.4×	47 0.2×	10	1.3k
Paul V. Fish United Kingdom	22	1.9k 2.1×	116 0.3×	247 0.7×	286 1.0×	648 2.3×	59	3.0k
Sérgio M. Marques Czechia	27	979 1.1×	102 0.3×	255 0.8×	282 0.9×	407 1.5×	61	1.8k
Zhihua Sui United States	28	949 1.0×	87 0.2×	74 0.2×	92 0.3×	1.5k 5.4×	123	2.7k
Bing Xiong China	26	1.5k 1.6×	87 0.2×	110 0.3×	291 1.0×	566 2.0×	143	2.3k

Countries citing papers authored by Jacques Ermolieff

Since Specialization

Citations

This map shows the geographic impact of Jacques Ermolieff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Ermolieff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Ermolieff more than expected).

Fields of papers citing papers by Jacques Ermolieff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Ermolieff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Ermolieff. The network helps show where Jacques Ermolieff may publish in the future.

Co-authorship network of co-authors of Jacques Ermolieff

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Ermolieff. A scholar is included among the top collaborators of Jacques Ermolieff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Ermolieff. Jacques Ermolieff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gurard‐Levin, Zachary A., Brian J. McMillan, Douglas A. Whittington, et al.. (2024). A duplexed high-throughput mass spectrometry assay for bifunctional POLB polymerase and lyase activity. SLAS TECHNOLOGY. 29(5). 100173–100173. 3 indexed citations

Grimshaw, Charles E., et al.. (2020). Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times. SLAS DISCOVERY. 26(5). 676–683.

Huang, Huey-Jing, Deepika Balakrishna, James Bilakovics, et al.. (2019). Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 371(2). 299–308. 6 indexed citations

Grimshaw, Charles E., Lihong Shi, Andre A. Kiryanov, et al.. (2017). Time-dependent inhibition of PHD2. Bioscience Reports. 37(3). 7 indexed citations

Vanderpool, Darin, Charles E. Grimshaw, J. David Lawson, & Jacques Ermolieff. (2014). Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors. Analytical Biochemistry. 473. 46–52. 1 indexed citations

Johnson, M. Catherine, Qiyue Hu, Laura Lingardo, et al.. (2011). Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery. Journal of Computer-Aided Molecular Design. 25(7). 689–698. 15 indexed citations

Nichols, Tim, Stephan K. Grant, Laura Lingardo, et al.. (2011). Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. Analytical Biochemistry. 414(2). 179–186. 22 indexed citations

Murphy, Sean T., Gordon Alton, Simon Bailey, et al.. (2010). Abstract 753: Novel, potent and selective small molecule inhibitors of 3-phosphoinositide-dependent kinase (PDK1). Cancer Research. 70(8_Supplement). 753–753. 2 indexed citations

Siu, Michael, Theodore Johnson, Yong Wang, et al.. (2009). N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorganic & Medicinal Chemistry Letters. 19(13). 3493–3497. 35 indexed citations

10.

Vanderpool, Darin, Ping Chen, Simon Bergqvist, et al.. (2009). Characterization of the CHK1 Allosteric Inhibitor Binding Site. Biochemistry. 48(41). 9823–9830. 37 indexed citations

11.

Bujalska, Iwona, Laura Gathercole, Jeremy Tomlinson, et al.. (2008). A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. Journal of Endocrinology. 197(2). 297–307. 68 indexed citations

12.

Zhu, Jeff, et al.. (2007). Assay optimization and kinetic profile of the human and the rabbit isoforms of 11β-HSD1. Biochemical and Biophysical Research Communications. 357(2). 561–566. 10 indexed citations

13.

Johnson, Theodore, Jacques Ermolieff, & Michael R. Jirousek. (2002). Protein tyrosine phosphatase 1B inhibitors for diabetes. Nature Reviews Drug Discovery. 1(9). 696–709. 564 indexed citations breakdown →

14.

Judd, Deborah A., James H. Nettles, Neysa Nevins, et al.. (2001). Polyoxometalate HIV-1 Protease Inhibitors. A New Mode of Protease Inhibition. Journal of the American Chemical Society. 123(5). 886–897. 338 indexed citations

15.

Ermolieff, Jacques, Jeffrey A. Loy, Gerald Koelsch, & Jordan Tang. (2000). Proteolytic Activation of Recombinant Pro-memapsin 2 (Pro-β-secretase) Studied with New Fluorogenic Substrates. Biochemistry. 39(51). 16263–16263. 20 indexed citations

16.

Ermolieff, Jacques, Xinli Lin, & Jordan Tang. (1998). The Effect of Substrates on the Kinetics and the in Vivo Threshold Activity of Mutant HIV-1 Proteases. Advances in experimental medicine and biology. 436. 47–51. 1 indexed citations

17.

Ermolieff, Jacques, et al.. (1998). Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: potent effect of O-butyrylated heparin. Biochemical Journal. 330(3). 1369–1374. 22 indexed citations

18.

Ermolieff, Jacques, Xinli Lin, & Jordan Tang. (1997). Kinetic Properties of Saquinavir-Resistant Mutants of Human Immunodeficiency Virus Type 1 Protease and Their Implications in Drug Resistance in Vivo. Biochemistry. 36(40). 12364–12370. 51 indexed citations

19.

Mellet, Philippe, Jacques Ermolieff, & Joseph G. Bieth. (1995). Mapping the Heparin-Binding Site of Mucus Proteinase Inhibitor. Biochemistry. 34(8). 2645–2652. 14 indexed citations

20.

Ermolieff, Jacques, Christian Boudier, Alexandra Lainé, Bernd Meyer, & Joseph G. Bieth. (1994). Heparin protects cathepsin G against inhibition by protein proteinase inhibitors.. Journal of Biological Chemistry. 269(47). 29502–29508. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact